Accurate Location of Catheter Tip With the Free-to-Total Metanephrine Ratio During Adrenal Vein Sampling.
adrenal vein sampling (AVS)
aldosterone
cortisol
metanephrines (plasma)
primary aldosteronism
secondary hypertension
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
12
2021
accepted:
31
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
26
4
2022
Statut:
epublish
Résumé
The selectivity index (SI) of cortisol is used to document correct catheter placement during adrenal vein sampling (AVS) in patients with primary aldosteronism (PA). We aimed to determine the cutoff values of the SIs based on cortisol, free metanephrine, and the free-to-total metanephrine ratio (FTMR) using an adapted AVS protocol in combination with CT. Adults with PA and referred for AVS were recruited in two hypertension centers. The cortisol and free metanephrine-derived SIs were calculated as the concentration of the analyte in adrenal veins divided by the concentration of the analyte in the distal vena cava. The FTMR-derived SI was calculated as the concentration of free metanephrine in the adrenal vein divided by that of total metanephrine in the ipsilateral adrenal vein. The AVS was classified as an unequivocal radiological success (uAVS) if the tip of the catheter was seen in the adrenal vein. The SI cutoffs of each index marker were established using receiver operating characteristic curve analysis. Out of 125 enrolled patients, 65 patients had an uAVS. The SI cutoffs were 2.6 for cortisol, 10.0 for free metanephrine, 0.31 for the FTMR on the left side, and 2.5, 9.9, and 0.25 on the right side. Compared to free metanephrine and the FTMR, cortisol misclassified AVS as unsuccessful in 36.6% and 39.0% of the cases, respectively. This study is the first to calculate the SIs of cortisol, free metanephrine, and the FTMR indices for the AVS procedure. It confirms that free metanephrine-based SIs are better than those based on cortisol.
Sections du résumé
Background
The selectivity index (SI) of cortisol is used to document correct catheter placement during adrenal vein sampling (AVS) in patients with primary aldosteronism (PA). We aimed to determine the cutoff values of the SIs based on cortisol, free metanephrine, and the free-to-total metanephrine ratio (FTMR) using an adapted AVS protocol in combination with CT.
Methods
Adults with PA and referred for AVS were recruited in two hypertension centers. The cortisol and free metanephrine-derived SIs were calculated as the concentration of the analyte in adrenal veins divided by the concentration of the analyte in the distal vena cava. The FTMR-derived SI was calculated as the concentration of free metanephrine in the adrenal vein divided by that of total metanephrine in the ipsilateral adrenal vein. The AVS was classified as an unequivocal radiological success (uAVS) if the tip of the catheter was seen in the adrenal vein. The SI cutoffs of each index marker were established using receiver operating characteristic curve analysis.
Results
Out of 125 enrolled patients, 65 patients had an uAVS. The SI cutoffs were 2.6 for cortisol, 10.0 for free metanephrine, 0.31 for the FTMR on the left side, and 2.5, 9.9, and 0.25 on the right side. Compared to free metanephrine and the FTMR, cortisol misclassified AVS as unsuccessful in 36.6% and 39.0% of the cases, respectively.
Conclusion
This study is the first to calculate the SIs of cortisol, free metanephrine, and the FTMR indices for the AVS procedure. It confirms that free metanephrine-based SIs are better than those based on cortisol.
Identifiants
pubmed: 35282466
doi: 10.3389/fendo.2022.842968
pmc: PMC8907625
doi:
Substances chimiques
Aldosterone
4964P6T9RB
Metanephrine
5001-33-2
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
842968Informations de copyright
Copyright © 2022 Christou, Pivin, Denys, Abid, Zingg, Matter, Pechère-Bertschi, Maillard, Grouzmann and Wuerzner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hypertension. 2013 Aug;62(2):331-6
pubmed: 23753408
Hypertension. 2020 Nov;76(5):1537-1544
pubmed: 32921192
J Clin Med. 2021 Oct 17;10(20):
pubmed: 34682878
J Clin Endocrinol Metab. 1995 Oct;80(10):3009-17
pubmed: 7559889
Lancet Diabetes Endocrinol. 2016 Sep;4(9):739-746
pubmed: 27325147
Endocr J. 2011;58(7):543-51
pubmed: 21521926
J Hypertens. 2011 Sep;29(9):1773-7
pubmed: 21720261
Hypertension. 2014 Jan;63(1):151-60
pubmed: 24218436
J Hypertens. 2012 Apr;30(4):761-9
pubmed: 22252482
Clin Exp Pharmacol Physiol. 1994 Apr;21(4):315-8
pubmed: 7923898
Hypertension. 2017 Aug;70(2):342-346
pubmed: 28584010
J Hypertens. 2018 Jun;36(6):1407-1413
pubmed: 29465715
Hypertension. 2013 Dec;62(6):1152-7
pubmed: 24082051
Lancet Diabetes Endocrinol. 2015 Apr;3(4):296-303
pubmed: 24831990
Hypertension. 2019 Oct;74(4):800-808
pubmed: 31476901
Ann Intern Med. 2001 Aug 21;135(4):258-61
pubmed: 11511140
J Hypertens. 1994 May;12(5):609-15
pubmed: 7930562
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Ann Intern Med. 2020 Jul 7;173(1):10-20
pubmed: 32449886
J Neurochem. 1996 Apr;66(4):1565-73
pubmed: 8627312
Clin Biochem. 2014 Aug;47(12):1121-3
pubmed: 24731790
Clin Chim Acta. 2014 Mar 20;430:125-8
pubmed: 24418619
Rev Endocr Metab Disord. 2001 Aug;2(3):297-311
pubmed: 11708294
Hypertension. 2016 Oct;68(4):989-94
pubmed: 27600182
Eur J Endocrinol. 2010 May;162(5):951-60
pubmed: 20142367
Hypertension. 2010 Mar;55(3):667-73
pubmed: 20124107
Toxicol Sci. 2006 Mar;90(1):5-22
pubmed: 16322073